• Lexaria management highlighted an extension of its Material Transfer Agreement with a global pharmaceutical partner through year-end 2026.
• CEO Rich Christopher told an investor interview the extension signals continued engagement around DehydraTECH, with additional data expected this year.
• Christopher outlined 2026 priorities focused on GLP-1 research, positioning results as a driver for partnering discussions.
• Business development activity was framed as part of a broader commercial strategy aimed at expanding partnering beyond GLP-1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202605070925TNWSWRCACNPR_____1ArbFWyWy) on May 07, 2026, and is solely responsible for the information contained therein.